• EVI

Initiation of Phase 1 Zika vaccine clinical trial

The ZIKAVAX consortium announced today the initiation of a Phase 1 clinical trial of a second-generation Zika vaccine. The vaccine candidate is based on one of the project partners -Themis- proprietary measles vector platform.

Source: Themis Biosciences GmbH

The observer-blinded, randomized trial will investigate the safety and tolerability of the novel Zika vaccine formulation in 48 healthy volunteers. The vaccine will be administered by intra-muscular injection in two different dose levels. Secondary objectives will include optimal dose-finding, immunogenicity and long-term safety evaluation, as well as cell-mediated immunity specific to the Zika antigen.

For the full press release, please follow this link.

Recent Posts

See All

Join European Vaccine Initiative mailing list for updates on projects, training and funding opportunities

© 2020 European Vaccine Initiative. Designed by European Vaccine Initiative